{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:44:55Z","timestamp":1793213095032,"version":"4.5.0"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients\u2019 age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggressive non-Hodgkin lymphomas, can augment the risk of secondary infections including CMV reactivation. In this real-world study, we described an increased incidence of CMV reactivation in older adults (age &gt;60 years old) with newly diagnosed and relapsed\/refractory indolent and aggressive diseases treated with bendamustine-containing regimens. In particular, patients who received bendamustine plus rituximab and dexamethasone were at higher risk of CMV reactivation, especially when administered as first-line therapy and after the third course of bendamustine. In addition, patients with CMV reactivation showed a significant depression of circulating CD4<jats:sup>+<\/jats:sup> T cell count and anti-CMV IgG levels during active infection, suggesting an impairment of immune system functions which are not able to properly face viral reactivation. Therefore, a close and early monitoring of clinical and laboratory findings might improve clinical management and outcome of non-Hodgkin lymphoma patients by preventing the development of CMV disease in a subgroup of subjects treated with bendamustine more susceptible to viral reactivation.<\/jats:p>","DOI":"10.1515\/med-2021-0274","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T14:26:09Z","timestamp":1619187969000},"page":"672-682","source":"Crossref","is-referenced-by-count":13,"title":["Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens"],"prefix":"10.1515","volume":"16","author":[{"given":"Luca","family":"Pezzullo","sequence":"first","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"},{"name":"Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"},{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno , Baronissi, 84081 , Salerno , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Fontana","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Guariglia","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"Martorelli","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idalucia","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mettivier","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bruno","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Bianco","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Vaccaro","sequence":"additional","affiliation":[{"name":"Transfusion Medicine, Molecular Biology Section, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pagliano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno , Baronissi, 84081 , Salerno , Italy"},{"name":"Infectious Disease Unit, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Montuori","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, \u201cFederico II\u201d University , 80138 , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Filippelli","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"},{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno , Baronissi, 84081 , Salerno , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d , Salerno, 84131 , Italy"},{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno , Baronissi, 84081 , Salerno , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"2022091918210252989_j_med-2021-0274_ref_001","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2022091918210252989_j_med-2021-0274_ref_002","doi-asserted-by":"crossref","unstructured":"Giudice V, Mensitieri F, Izzo V, Filippelli A, Selleri C. Aptamers and antisense oligonucleotides for diagnosis and treatment of hematological diseases. Int J Mol Sci. 2020;21(9):3252.","DOI":"10.3390\/ijms21093252"},{"key":"2022091918210252989_j_med-2021-0274_ref_003","doi-asserted-by":"crossref","unstructured":"Cozzolino I, Giudice V, Mignogna C, Selleri C, Caputo A, Zeppa P. Lymph node fine-needle cytology in the era of personalised medicine. Is there a role? Cytopathology. 2019;30(4):348\u201362.","DOI":"10.1111\/cyt.12708"},{"key":"2022091918210252989_j_med-2021-0274_ref_004","doi-asserted-by":"crossref","unstructured":"Fisher SG, Fisher RI. The epidemiology of non-Hodgkin\u2019s lymphoma. Oncogene. 2004;23(38):6524\u201334.","DOI":"10.1038\/sj.onc.1207843"},{"key":"2022091918210252989_j_med-2021-0274_ref_005","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Garc\u00eda G, Colomo L, Villamor N, Arenillas L, Mart\u00ednez A, Cardesa T, et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2010;51(7):1225\u201332.","DOI":"10.3109\/10428194.2010.483301"},{"key":"2022091918210252989_j_med-2021-0274_ref_006","doi-asserted-by":"crossref","unstructured":"Sun R, Medeiros LJ, Young KH. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol. 2016;29(10):1118\u201342.","DOI":"10.1038\/modpathol.2016.92"},{"key":"2022091918210252989_j_med-2021-0274_ref_007","doi-asserted-by":"crossref","unstructured":"Darwiche W, Gubler B, Marolleau JP, Ghamlouch H. Chronic lymphocytic leukemia B-cell normal cellular counterpart: clues from a functional perspective. Front Immunol. 2018;9:683.","DOI":"10.3389\/fimmu.2018.00683"},{"key":"2022091918210252989_j_med-2021-0274_ref_008","doi-asserted-by":"crossref","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis; risk stratification; and treatment. Am J Hematol. 2017;92:946\u201365.","DOI":"10.1002\/ajh.24826"},{"key":"2022091918210252989_j_med-2021-0274_ref_009","doi-asserted-by":"crossref","unstructured":"International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"2022091918210252989_j_med-2021-0274_ref_010","doi-asserted-by":"crossref","unstructured":"Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018;93(2):296\u2013305.","DOI":"10.1002\/ajh.24937"},{"key":"2022091918210252989_j_med-2021-0274_ref_011","doi-asserted-by":"crossref","unstructured":"Hagemeister F, Manoukian G. Bendamustine in the treatment of non-Hodgkin\u2019s lymphomas. Onco Targets Ther. 2009;2:269\u201379.","DOI":"10.2147\/OTT.S4873"},{"key":"2022091918210252989_j_med-2021-0274_ref_012","doi-asserted-by":"crossref","unstructured":"Hartmann M, Zimmer CH. Investigation of cross-link formation in DNA by alkylating cytostatic IMET 3106, 3393 and 3943. Biochem Biophys Acta. 1972;287:386\u20139.","DOI":"10.1016\/0005-2787(72)90282-1"},{"key":"2022091918210252989_j_med-2021-0274_ref_013","doi-asserted-by":"crossref","unstructured":"Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309\u201317.","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"2022091918210252989_j_med-2021-0274_ref_014","doi-asserted-by":"crossref","unstructured":"Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31(17):2103\u20139.","DOI":"10.1200\/JCO.2012.46.5203"},{"key":"2022091918210252989_j_med-2021-0274_ref_015","doi-asserted-by":"crossref","unstructured":"Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, et al. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 2016;175(2):281\u20139.","DOI":"10.1111\/bjh.14232"},{"key":"2022091918210252989_j_med-2021-0274_ref_016","doi-asserted-by":"crossref","unstructured":"Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31:104\u201310.","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"2022091918210252989_j_med-2021-0274_ref_017","doi-asserted-by":"crossref","unstructured":"Gil L, Kazmierczak M, Kroll-Balcerzak R, Komarnicki M. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. Med Oncol. 2014;31(5):944.","DOI":"10.1007\/s12032-014-0944-1"},{"key":"2022091918210252989_j_med-2021-0274_ref_018","doi-asserted-by":"crossref","unstructured":"Fung M, Jacobsen E, Freedman A, Prestes D, Farmakiotis D, Gu X, et al. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 2019;68(2):247\u201355.","DOI":"10.1093\/cid\/ciy458"},{"key":"2022091918210252989_j_med-2021-0274_ref_019","doi-asserted-by":"crossref","unstructured":"Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984\u201391.","DOI":"10.1200\/JCO.18.00605"},{"key":"2022091918210252989_j_med-2021-0274_ref_020","doi-asserted-by":"crossref","unstructured":"Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 2015;5(10):e362.","DOI":"10.1038\/bcj.2015.86"},{"key":"2022091918210252989_j_med-2021-0274_ref_021","doi-asserted-by":"crossref","unstructured":"Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202\u201313.","DOI":"10.1002\/rmv.655"},{"key":"2022091918210252989_j_med-2021-0274_ref_022","doi-asserted-by":"crossref","unstructured":"Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol. 2001;54(2):84\u20138.","DOI":"10.1136\/jcp.54.2.84"},{"key":"2022091918210252989_j_med-2021-0274_ref_023","doi-asserted-by":"crossref","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332.","DOI":"10.1182\/blood-2011-01-293050"},{"key":"2022091918210252989_j_med-2021-0274_ref_024","doi-asserted-by":"crossref","unstructured":"Torres HA, Kontoyiannis DP, Aguilera EA, Younes A, Luna MA, Tarrand JJ, et al. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin Lymphoma Myeloma. 2006;6(5):393\u20138.","DOI":"10.3816\/CLM.2006.n.016"},{"key":"2022091918210252989_j_med-2021-0274_ref_025","unstructured":"Singhania SVK, Parikh P, Goyle S. CMV pneumonitis following bendamustine containing chemotherapy. J Assoc Physicians India. 2017;65(9):92\u20133."},{"key":"2022091918210252989_j_med-2021-0274_ref_026","doi-asserted-by":"crossref","unstructured":"Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, et al. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leuk Lymphoma. 2016;57(9):2204\u20137.","DOI":"10.3109\/10428194.2015.1126589"},{"key":"2022091918210252989_j_med-2021-0274_ref_027","doi-asserted-by":"crossref","unstructured":"Hasegawa T, Aisa Y, Shimazaki K, Nakazato T. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma. Ann Hematol. 2015;94(3):515\u20137.","DOI":"10.1007\/s00277-014-2182-1"},{"key":"2022091918210252989_j_med-2021-0274_ref_028","doi-asserted-by":"crossref","unstructured":"Cona A, Tesoro D, Chiamenti M, Merlini E, Ferrari D, Marti A, et al. Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. BMC Infect Dis. 2019;19(1):881.","DOI":"10.1186\/s12879-019-4545-7"},{"key":"2022091918210252989_j_med-2021-0274_ref_029","doi-asserted-by":"crossref","unstructured":"Lim SH, Pathapati S, Langevin J, Hoot A. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol. 2012;91(4):643\u20134.","DOI":"10.1007\/s00277-011-1307-z"},{"key":"2022091918210252989_j_med-2021-0274_ref_030","doi-asserted-by":"crossref","unstructured":"Modvig L, Boyle C, Randall K, Borg A. Severe cytomegalovirus reactivation in patient with low-grade non-Hodgkin\u2019s lymphoma after standard chemotherapy. Case Rep Hematol. 2017;2017:5762525.","DOI":"10.1155\/2017\/5762525"},{"key":"2022091918210252989_j_med-2021-0274_ref_031","doi-asserted-by":"crossref","unstructured":"Hosoda T, Yokoyama A, Yoneda M, Yamamoto R, Ohashi K, Kagoo T, et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma. 2013;54(6):1327\u20138.","DOI":"10.3109\/10428194.2012.739285"},{"key":"2022091918210252989_j_med-2021-0274_ref_032","doi-asserted-by":"crossref","unstructured":"Yamasaki S, Kohno K, Kadowaki M, Takase K, Iwasaki H. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine. Ann Hematol. 2017;96(7):1215\u20137.","DOI":"10.1007\/s00277-017-3005-y"},{"key":"2022091918210252989_j_med-2021-0274_ref_033","doi-asserted-by":"crossref","unstructured":"Ito K, Okamoto M, Ando M, Kakumae Y, Okamoto A, Inaguma Y, et al. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2015;56(4):1123\u20135.","DOI":"10.3109\/10428194.2014.921298"},{"key":"2022091918210252989_j_med-2021-0274_ref_034","doi-asserted-by":"crossref","unstructured":"Yutaka T, Ito S, Ohigashi H, Naohiro M, Shimono J, Souichi S, et al. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. Leuk Lymphoma. 2015;56(11):3216\u20138.","DOI":"10.3109\/10428194.2015.1026818"},{"key":"2022091918210252989_j_med-2021-0274_ref_035","doi-asserted-by":"crossref","unstructured":"Garc\u00eda Mu\u00f1oz R, Izquierdo-Gil A, Mu\u00f1oz A, Roldan-Galiacho V, Rabasa P, Panizo C. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 2014;93(11):1879\u201387.","DOI":"10.1007\/s00277-014-2135-8"},{"key":"2022091918210252989_j_med-2021-0274_ref_036","doi-asserted-by":"crossref","unstructured":"Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel). 2015;7(1):305\u201328.","DOI":"10.3390\/cancers7010305"},{"key":"2022091918210252989_j_med-2021-0274_ref_037","doi-asserted-by":"crossref","unstructured":"Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002;100(5):1765\u201373.","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773"},{"key":"2022091918210252989_j_med-2021-0274_ref_038","doi-asserted-by":"crossref","unstructured":"Hemmersbach-Miller M, Alexander BD, Pieper CF, Schmader KE. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient. Eur J Clin Microbiol Infect Dis. 2020;39(3):455\u201363.","DOI":"10.1007\/s10096-019-03744-3"},{"key":"2022091918210252989_j_med-2021-0274_ref_039","doi-asserted-by":"crossref","unstructured":"Stern L, Withers B, Avdic S, Gottlieb D, Abendroth A, Blyth E, et al. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol. 2019;10:1186.","DOI":"10.3389\/fmicb.2019.01186"},{"key":"2022091918210252989_j_med-2021-0274_ref_040","doi-asserted-by":"crossref","unstructured":"Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan society for hematopoietic cell transplantation transplantation-related complication working group. Biol Blood Marrow Transplant. 2015;21(11):2008\u201316.","DOI":"10.1016\/j.bbmt.2015.07.019"},{"key":"2022091918210252989_j_med-2021-0274_ref_041","doi-asserted-by":"crossref","unstructured":"Slade M, Goldsmith S, Romee R, DiPersio JF, Dubberke ER, Westervelt P, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017;19(1):e12629.","DOI":"10.1111\/tid.12629"},{"key":"2022091918210252989_j_med-2021-0274_ref_042","doi-asserted-by":"crossref","unstructured":"Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673\u201385.","DOI":"10.1084\/jem.20050882"},{"key":"2022091918210252989_j_med-2021-0274_ref_043","doi-asserted-by":"crossref","unstructured":"Isono N, Imai Y, Asano C, Masuda M, Hoshino S, Moriya K, et al. Prospective analysis of cytomegalovirus reactivation and the immune state of low-grade B-cell lymphoma patients treated with bendamustine. Blood. 2014;124(21):4411.","DOI":"10.1182\/blood.V124.21.4411.4411"},{"key":"2022091918210252989_j_med-2021-0274_ref_044","doi-asserted-by":"crossref","unstructured":"Lim EY, Jackson SE, Wills MR. The CD4+ T cell response to human cytomegalovirus in healthy and immunocompromised people. Front Cell Infect Microbiol. 2020;10:202.","DOI":"10.3389\/fcimb.2020.00202"},{"key":"2022091918210252989_j_med-2021-0274_ref_045","doi-asserted-by":"crossref","unstructured":"van der Heiden PLJ, van Egmond HM, Veld SAJ, van de Meent M, Eefting M, de Wreede LC, et al. CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity. Transpl Immunol. 2018;49:54\u20138.","DOI":"10.1016\/j.trim.2018.04.003"},{"key":"2022091918210252989_j_med-2021-0274_ref_046","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Ravandi-Kashani F, Wierda WG, Giles F, Thomas D, Huang X, et al. A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. Blood. 2005;106(11):2960.","DOI":"10.1182\/blood.V106.11.2960.2960"},{"key":"2022091918210252989_j_med-2021-0274_ref_047","unstructured":"Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposito S, et al. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation. Infez Med. 2012;20(2):26\u201334."}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0274\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T18:31:28Z","timestamp":1663612288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0274\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,5,14]]},"published-print":{"date-parts":[[2021,5,14]]}},"alternative-id":["10.1515\/med-2021-0274"],"URL":"https:\/\/doi.org\/10.1515\/med-2021-0274","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}